Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Levomequitazine - Pierre Fabre

Next Previous
Drug Profile

Levomequitazine - Pierre Fabre

Alternative Names: (-)-mequitazine; (S)-mequitazine; L-mequitazine; V0114; V0114CP

Latest Information Update: 10 Aug 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pierre Fabre
  • Class Antiallergics; Phenothiazines; Sedating antihistamines; Small molecules
  • Mechanism of Action Histamine H1 receptor antagonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Perennial allergic rhinitis; Seasonal allergic rhinitis

Most Recent Events

  • 10 Aug 2021 Discontinued - Phase-III for Perennial allergic rhinitis in Spain, Latvia, Austria, United Kingdom, Estonia, Lithuania, Finland, Czech Republic (PO) (Pierre Fabre pipeline, August 2021)
  • 10 Aug 2021 Discontinued - Phase-III for Seasonal allergic rhinitis in Czech Republic, Estonia, France, Latvia, Poland, Denmark, Spain, Italy, Hungary, Belgium, Lithuania, Slovakia, Germany (PO) (Pierre Fabre pipeline, August 2021)
  • 19 May 2009 Pierre Fabre completes a phase III trial in Seasonal allergic rhinitis in Poland, Belgium (PO) (EudraCT2008-008734-36)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top